Download PDF
Arzneimittelforschung 2009; 59(6): 297-302
DOI: 10.1055/s-0031-1296400
Anticoagulants · Antithrombotics · Antivaricosis · Blood Flow Stimulants
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence Study of Two Different Clopidogrel Bisulfate Film-coated Tablets

Wolfram Richter
1   Cooperative Clinical Drug Research and Development AG, Berlin, (Germany)
,
Aydin Erenmemisoglu
2   Erciyes University School of Medicine, Hakan Cetinsaya GCP Clinical Research Center, Kayseri, (Turkey)
,
Mike John Van Der Meer
3   Trident Bioanalytics Limited, Cork, (Ireland)
,
Nizam Emritte
4   Drogsan Pharmaceuticals, Ankara, (Turkey)
,
Tuncay Emine
4   Drogsan Pharmaceuticals, Ankara, (Turkey)
,
Rossen Koytchev
1   Cooperative Clinical Drug Research and Development AG, Berlin, (Germany)
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2011 (online)

    Permissions and Reprints

Abstract

Objective:

The aim of the present study was to evaluate the bioequivalence of two oral clopidogrel (CAS 113665-84-2) formulations.

Method:

The study was conducted as a monocentric, open, randomized, single-dose, two-period crossover trial in 48 healthy volunteers with a duration of hospitalization of approximately 24 h after dosing on day 1 and with a real wash-out period of 7 days.

Blood samples were collected for 24 h post dosing in each period. The plasma was separated and the concentrations of clopidogrel were determined by a LC-MS/MS method. AUC0–tlast, Cmax, t max, AUC0–inf, MRT and t 1/2 were calculated for both formulations.

Results:

The arithmetic means of AUC0–tlast and C max were 3656.01 pg · h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg · h/ml and 1756.52 pg/ml, respectively, for the reference formulation. The mean t max was 1.16 h for the test and 1.13 h for the reference formulation. The point estimators of the ratios of the test and reference formulations for AUC0–tlast and C max were 1.042 and 1.115, respectively. Furthermore, the 90% confidence intervals calculated by means of ANOVA-log for the first primary endpoint of the trial, the intra-individual ratio (T/R) of AUC0–tlast of clopidogrel was between 0.932 and 1.165. The 90% confidence interval calculated by means of ANOVA-log for C max of clopidogrel was between 0.973 and 1.277. The 90% confidence intervals for both parameters were within the predefined acceptance ranges (0.80–1.25 for AUC0–tlast and 0.75–1.33 for C max ). The intraindividual coefficients of variation determined by means of ANOVA-log were 33.51% for AUC0–tlast and 41.29% for Cmax.

Conclusion:

While both products were bioequivalent in terms of the rate and extent of absorption, the present study also confirmed a high variability for Clopidogrel suggesting high volunteer numbers in bioequivalence trials.

Key words

CAS 113665-84-2 - clopidogrel, bioequivalence, clinical pharmacokinetics, highly variable drug, replicate trial design - Platelet aggregation inhibitors
 

  • References

  • 1 Prescribing Information Plavix®. USA: Bristol-Myers Squibb/Sanofi Pharmaceuticals; Jan 2005
    PubMedGoogle Scholar
  • 2 Plosker GL, Lyseng-Williamson KA. Clopidogrel: A Review of its Use in the Prevention of Thrombosis. Drugs. 2007; 67 (4) 613-46
    CrossrefPubMedGoogle Scholar
  • 3 ICH Topic E 6. Guideline for Good Clinical Practice. Step 5, Consolidated Guideline from 01. 05. 1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Jan. 1997
    PubMedGoogle Scholar
  • 4 Heinzel G, Woloszczak R. Thomann (eds.) TopFit 2.0, pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer; 1993
  • 5 Questions & Answers on the Bioavailability and Bioequivalence Guideline (EMEA/CHMP/EWP/40326/2006).
    PubMed
  • 6 CPMP Draft Guideline On The Investigation Of Bioequivalence. (CPMP/EWP/QWP/1401/98 Rev. 1); July 2008
    PubMedGoogle Scholar
  • 7 Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28 (2) 72-8
    PubMedGoogle Scholar
  • 8 Amidon GL, Lennernas H, Shah VP, Crison JR. A Theoretical basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm. Res. 1995; 12: 413-20
    CrossrefPubMedGoogle Scholar
  • 9 Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20 (11) 1695-700
    CrossrefPubMedGoogle Scholar
  • 10 Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol. 2000; 40 (4) 396-401
    CrossrefPubMedGoogle Scholar
  • 11 Shin BS, Yoo SD. Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed Chromatogr. 2007; 21 (9) 883-9
    CrossrefPubMedGoogle Scholar
  • 12 Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioquivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004; 54 (9 a) 600-4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999; 25 (Suppl. 2) 25-8
    PubMedGoogle Scholar